Quinuclidinone derivative 6 induced apoptosis in human breast cancer cells via sphingomyelinase and JNK signaling

Journal of Chemotherapy

Volumn 24, Issue 5, 2012, Pages 268-278

  Malki, Ahmed ^a   El Ashry, El Sayed ^a  

^a Alexandria University Faculty Of Science   (Egypt)

Author keywords

Anticancer derivatives; Bax; Cell cycle; JNK; P38; P53; Sphingomyelinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 9; CERAMIDE; CYCLIN B; CYTOCHROME C; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; QUINUCLIDINE DERIVATIVE; QUINUCLIDINONE 4; QUINUCLIDINONE 6; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRION; MOLECULAR DOCKING; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CERAMIDES; CYCLIN B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; QUINUCLIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 84866660060     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000035     Document Type: Article

References (37)

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer epidemiology, risk factors, and genetics. Br Med J. 2000;321:624-62.
2. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001;7:548-52.
3. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol. 1997;6:142.
4. Hendrickx N, Volanti C, Moens U. Up-regulation of cycloox-ygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem. 2003;278:52231-9.
5. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989;246:629-34.
6. Paulovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell. 1997;88:315-21.
7. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and DNA damage checkpoints. Annu Rev Biochem. 2004;73:39-85.
8. Muller M, Wilder S, Bannasch D. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033-45.
9. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-56.
10. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998;12:2973-83.
11. Malki A, Bergmeier S. Differential apoptotic effects of novel quinuclidinone analogs 8a and 8b in normal and lung cancer cell lines. Anticancer Res. 2011;31:1345-58.
12. Malki A, Bergmeier S. Novel quinuclidinone derivative 8a induced apoptosis in human MCF-7 breast cancer cell lines. Anticancer Res. 2011;31(6):871-81.
13. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994;29:127-38.
14. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-53.
15. Fisher DE. Apoptosis in cancer therapy. crossing the threshold. Cell. 1994;78:539-42.
16. Lowe SW, Ruley HE, Jacks T. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-67.
17. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131-4.
18. Morgan DO. Cyclin dependent kinases; engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261-91.
19. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21 Cipl/Wafl by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001;3:245-51.
20. Xie XH, An HJ, Kang S. Loss of cyclin B1 followed by downregulation of cyclin A/Cdk2, apoptosis and antiprolifera-tion in HeLa cell line. Int J Cancer. 2005;116:520-5.
21. El-Deiry WS, Tokino T, Velculescu VE. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.
22. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821-8.
23. Yao SL, Akhtar AJ, McKenna KA. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med. 1996;2:1140-3.
24. Momand J, Zambetti G, Olson D. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-45.
25. Haupt Y, Maya R, Kazaz A. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-9.
26. Marone M, Scambia G, Mozetti S. Bcl-2, bax, bcl-XL, and bcl-XS in normal and neoplastic ovarian tissues. Clin Cancer Res. 1998;4:517-24.
27. Herod J, Eliopoulos A, Warwick J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996;56:2178-84.
28. Cory S, Adams JM. The Bc12 family regulators of the cellular life or death switch. Nat Rev Cancer. 2002;2:647-56.
29. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. Blood. 1998;92:1768-75.
30. Zhang Z, Leonard SS, Huang C, Vallyathan V, Castranova V, Shi X. Role of reactive oxygen species and MAPKs in vanadate-induced G2/M phase arrest. Free Radic Biol Med. 2003;34:1333-42.
31. Wang X, McGowan CH, Zhao M, He L, Downey JS, Fearns C, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest Mol Cell Biol. 2000;20:4543-52.
32. Frey RS, Singletary KW. Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. J Nutr. 2003;133:226-31.
33. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-52
34. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004;279:12755-62.
35. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004;10 125-129.
36. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-4.
37. Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM. prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem J. 1996;316:25-8.